semaglutide tracker app App: Easy Tracking for Effective Weight Loss Best Weight Tracking Apps :

Wegovy got FDA approval in 2021 specifically for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related health condition

Participants received either semaglutide 2.4 mg weekly or placebo, combined with lifestyle intervention, for 68 weeks

InCare coordinates with your diabetes care team to ensure safe, effective treatment that addresses both conditions simultaneously.

To report suspected adverse reactions to Wegovy contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

*Eligible patients lost an average of 15% of their body weight (-33.6 lbs) in a 68-week clinical trial evaluating 2.4 mg semaglutide, when paired with diet and exercise